Why Diversity Still Should Matter

Despite talking about diversity in clinical trials for years, real progress is still too slow. This webinar takes a hard look at what’s holding the industry back and why getting it right in 2026 isn’t optional; it’s essential for science, safety, and patients. Panelists include Kemi Williams, PhD, MBA (consultant), Leida Bowen, PharmD, (AbbVie), and Natalie Monegro (Novo Nordisk).